Drugs / GSK2330811
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT04138043 | Dec 2019 → May 2020 | — | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT02386436 | Apr 2015 → Apr 2016 | systemic sclerosis | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT04151225 | Apr 2021 → Apr 2024 | Crohn disease | GlaxoSmithKline | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT03041025 | Jun 2017 → Jul 2020 | systemic sclerosis | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GSK2330811 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02386436 ↗ |
| Action | Inhibit | “blocks Oncostatin M (OSM)” NCT02386436 ↗ |
| Modality | Monoclonal antibody | “an anti-OSM monoclonal antibody (GSK2330811) in healthy volunteers” PMID 38501358 ↗ Mar 2024 |
| Route | Subcutaneous | “administered as single dose s.c.” NCT02386436 ↗ |
| Target | OSM | “blocks Oncostatin M (OSM)” NCT02386436 ↗ |